Corcept Therapeutics - CORT Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CORT shares.
View CORT analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month price targets for Corcept Therapeutics' shares. Their CORT share price forecasts range from $30.00 to $35.00. On average, they anticipate the company's share price to reach $32.00 in the next year. This suggests a possible upside of 24.8% from the stock's current price.
View analysts price targets for CORT or view top-rated stocks among Wall Street analysts.

Corcept Therapeutics' stock was trading at $19.80 on January 1st, 2022. Since then, CORT stock has increased by 29.5% and is now trading at $25.64.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CORT earnings forecast.

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its earnings results on Wednesday, August, 3rd. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by $0.01. The biotechnology company earned $103.39 million during the quarter, compared to analyst estimates of $101.51 million. Corcept Therapeutics had a trailing twelve-month return on equity of 25.53% and a net margin of 28.75%.

Corcept Therapeutics issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $400.00 million-$430.00 million, compared to the consensus revenue estimate of $414.43 million.

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CORT stock can currently be purchased for approximately $25.64.

Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $2.75 billion and generates $365.98 million in revenue each year. The biotechnology company earns $112.51 million in net income (profit) each year or $0.94 on an earnings per share basis.

The company employs 238 workers across the globe.

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218.